Ethylparaben is a widely used preservative found in personal care products, processed foods, and pharmaceuticals, with increasing concerns about its role as an endocrine-disrupting chemical (EDC).
While regulatory agencies have deemed it safe at low levels, emerging research suggests that cumulative exposure may contribute to hormonal imbalances, metabolic disruptions, and potential risks for hormone-sensitive conditions.
Ethylparaben, or E214, is a widely used preservative in cosmetics, pharmaceuticals, and food and alcohol products. It is an ethyl ester of p-hydroxybenzoic acid (PHBA) and has antimicrobial properties that help prevent microbial contamination and extend product shelf life.
Human exposure occurs through skin absorption, ingestion, and environmental contamination, as ethylparaben has been detected in personal care products, food, some alcoholic beverages, and drinking water.
While ethylparaben has been considered safe at low levels, growing evidence suggests potential endocrine-disrupting effects, particularly with long-term exposure.
Ethylparaben is a biomarker of environmental and chemical exposure, offering insights into paraben absorption, metabolism, and excretion. It can be detected in human urine, blood, breast milk, and seminal plasma, reflecting both acute and chronic exposure levels.
Public health agencies, such as the Centers for Disease Control and Prevention (CDC), track ethylparaben levels through biomonitoring studies to assess population-wide exposure trends.
Research suggests that higher ethylparaben levels may correlate with increased risks of metabolic disorders, endocrine dysfunction, and even certain cancers.
While short-term exposure is unlikely to cause harm, cumulative exposure from multiple sources (cosmetics, processed foods, alcohol, pharmaceuticals) may increase the risk of hormone disruption and metabolic changes.
Parabens are a type of endocrine-disrupting chemical which may have unwanted health effects.
Endocrine-disrupting chemicals (EDCs) are substances that interfere with natural hormone function, affecting metabolism, fat storage, reproductive health, and overall endocrine balance.
These compounds mimic, block, or alter hormone signals, potentially disrupting weight regulation, fertility, and hormone-sensitive diseases.
EDCs—including parabens, bisphenols, and phthalates—are found in plastics, pesticides, personal care products, and processed foods. Some EDCs, including ethylparaben and other parabens, are known as obesogens because they contribute to weight gain and fat accumulation by increasing fat cell production (adipogenesis) and altering metabolic pathways.
Parabens, including ethylparaben, are classified as weak estrogenic compounds due to their ability to bind to estrogen receptors. Their endocrine activity increases with longer alkyl chain lengths, meaning butylparaben and propylparaben have stronger hormonal effects than methylparaben and ethylparaben.
Due to their lipophilic nature, parabens accumulate in body fat, increasing the potential for long-term hormonal imbalances. Paraben exposure has been linked to:
The European Union has restricted certain parabens in infant skincare products due to safety concerns.
Ethylparaben is absorbed through the skin and gastrointestinal tract and metabolized primarily in the liver. However, studies suggest that human skin metabolism is less efficient than previously thought, allowing unmetabolized parabens to enter circulation and exert systemic endocrine effects.
Testing should be considered for:
Ethylparaben exposure is primarily assessed through urine testing, the most reliable method, using high-performance liquid chromatography (HPLC) or mass spectrometry (LC-MS/MS). Blood tests can detect parabens but are less reliable due to rapid metabolism.
Breast milk, saliva, and seminal plasma testing can also measure exposure, though these methods are less commonly used and may be more common in research settings.
Elevated ethylparaben levels in biological samples, such as urine, blood, and breast milk, indicate significant exposure from personal care products, processed foods, and environmental contaminants.
While regulatory agencies consider low-dose exposure safe, higher levels have been associated with potential endocrine-disrupting effects and emerging health concerns, including:
Hormonal Imbalances: Ethylparaben mimics estrogen and may disrupt endocrine function, leading to altered estradiol, testosterone, and thyroid hormone function and/or availability.
Reproductive Health Risks: Some research links parabens to reduced ovarian follicle count, menstrual irregularities, and lower pregnancy rates.
Metabolic Dysfunction: Activation of PPAR-γ may contribute to increased fat storage, obesity, and insulin resistance, heightening the risk for metabolic syndrome.
Potential Cancer Risk: Ethylparaben has been detected in breast cancer tissues, including tumor-adjacent regions, raising concerns about hormone-sensitive malignancies.
Cumulative Bioaccumulation: Ethylparaben is lipophilic, meaning repeated exposure may lead to accumulation in fat tissue.
Individuals with high ethylparaben levels may benefit from reducing exposure, particularly those with hormonal disorders, metabolic conditions, or infertility concerns.
Low or undetectable ethylparaben levels suggest minimal recent exposure to paraben-containing products. While this may indicate reduced risk of endocrine disruption, it does not necessarily imply complete avoidance, as parabens can be rapidly metabolized and excreted.
Lower Exposure to Endocrine Disruptors: Reduced ethylparaben levels may correlate with limited use of paraben-containing cosmetics, personal care products, and processed foods.
Potential for Reduced Hormonal Impact: Lower ethylparaben levels may decrease the likelihood of estrogenic and anti-androgenic effects, which may be beneficial for individuals with hormone-sensitive conditions.
Environmental and Lifestyle Factors: Some populations, such as those following organic or clean beauty lifestyles, may naturally have lower ethylparaben exposure.
However, low levels alone do not rule out other sources of endocrine disruption, as exposure to alternative parabens, bisphenols, or phthalates may still occur. Regular biomonitoring and comprehensive toxicant screening may be warranted in cases of persistent hormonal imbalances.
Albouy M, Deceuninck Y, Migeot V, Doumas M, Dupuis A, Venisse N, Engene PP, Veyrand B, Geny T, Marchand P, Le Bizec B, Bichon E, Carato P. Characterization of pregnant women exposure to halogenated parabens and bisphenols through water consumption. J Hazard Mater. 2023 Apr 15;448:130945. doi: 10.1016/j.jhazmat.2023.130945. Epub 2023 Feb 6. PMID: 36758432.
Azeredo DBC, de Sousa Anselmo D, Soares P, Graceli JB, Magliano DC, Miranda-Alves L. Environmental Endocrinology: Parabens Hazardous Effects on Hypothalamic-Pituitary-Thyroid Axis. Int J Mol Sci. 2023 Oct 17;24(20):15246. doi: 10.3390/ijms242015246. PMID: 37894927; PMCID: PMC10607526.
Darbre PD. Endocrine Disruptors and Obesity. Curr Obes Rep. 2017 Mar;6(1):18-27. doi: 10.1007/s13679-017-0240-4. PMID: 28205155; PMCID: PMC5359373.
Exposure to and toxicity of methyl-, ethyl-and propylparaben A literature review with a focus on endocrine-disrupting properties. (n.d.). https://www.rivm.nl/bibliotheek/rapporten/2017-0028.pdf
Karwacka A, Zamkowska D, Radwan M, Jurewicz J. Exposure to modern, widespread environmental endocrine disrupting chemicals and their effect on the reproductive potential of women: an overview of current epidemiological evidence. Hum Fertil (Camb). 2019 Apr;22(1):2-25. doi: 10.1080/14647273.2017.1358828. Epub 2017 Jul 31. PMID: 28758506.
Kiwitt-Cárdenas J, Arense-Gonzalo JJ, Adoamnei E, Sarabia-Cos L, Vela-Soria F, Fernández MF, Gosálvez J, Mendiola J, Torres-Cantero AM. Urinary concentrations of bisphenol A, parabens and benzophenone-type ultra violet light filters in relation to sperm DNA fragmentation in young men: A chemical mixtures approach. Sci Total Environ. 2024 Feb 20;912:169314. doi: 10.1016/j.scitotenv.2023.169314. Epub 2023 Dec 15. PMID: 38103620.
Kolatorova L, Sramkova M, Vitku J, Vcelak J, Lischkova O, Starka L, Duskova M. Parabens and their relation to obesity. Physiol Res. 2018 Nov 28;67(Suppl 3):S465-S472. doi: 10.33549/physiolres.934004. PMID: 30484673.
Mao W, Qu J, Zhong S, Wu X, Mao K, Liao K, Jin H. Associations between urinary parabens and lung cancer. Environ Sci Pollut Res Int. 2023 May;30(24):66186-66194. doi: 10.1007/s11356-023-26953-y. Epub 2023 Apr 25. PMID: 37097579.
MarkerDB. (2023). Markerdb.ca. https://markerdb.ca/conditions/6928
Matwiejczuk N, Galicka A, Brzóska MM. Review of the safety of application of cosmetic products containing parabens. J Appl Toxicol. 2020 Jan;40(1):176-210. doi: 10.1002/jat.3917. PMID: 31903662.
National Institute of Environmental Health Sciences. (2024, July 22). Endocrine Disruptors. National Institute of Environmental Health Sciences. https://www.niehs.nih.gov/health/topics/agents/endocrine
Scientific Committee on Consumer Safety SCCS Clarification on Opinion SCCS/1348/10 in the light of the Danish clause of safeguard banning the use of parabens in cosmetic products intended for children under three years of age. (2011). https://doi.org/10.2772/20395
Song Y, Wang M, Nie L, Liao W, Wei D, Wang L, Wang J, Xu Q, Huan C, Jia Z, Mao Z, Wang C, Huo W. Exposure to parabens and dysglycemia: Insights from a Chinese population. Chemosphere. 2023 Nov;340:139868. doi: 10.1016/j.chemosphere.2023.139868. Epub 2023 Aug 17. PMID: 37597620.
Srnovršnik T, Virant-Klun I, Pinter B. Polycystic Ovary Syndrome and Endocrine Disruptors (Bisphenols, Parabens, and Triclosan)-A Systematic Review. Life (Basel). 2023 Jan 4;13(1):138. doi: 10.3390/life13010138. PMID: 36676087; PMCID: PMC9864804.